Early Weight-Bearing After the Lapiplasty Procedure (ALIGN3D)

September 19, 2023 updated by: Treace Medical Concepts, Inc.

Prospective Clinical StuDy of Tri-planar Tarsometatarsal (TMT) ArthroDesIs With Early WeiGht-BeariNg After Lapiplasty ProcDure (ALIGN3D)

The objectives of this study are to evaluate the following outcomes of the Lapiplasty® Procedure for patients in need of hallux valgus surgery:

  • The study will determine the radiographic recurrence of hallux valgus and the timing of failure following hallux valgus correction with the Lapiplasty® Procedure.
  • The study will determine whether the Lapiplasty® Procedure effectively corrects anatomical alignment of the 1st metatarsal and sesamoids in all three planes.
  • The study will assess whether early weight-bearing after the Lapiplasty® Procedure affects the union rates or causes loss of 3-plane correction.
  • The study will evaluate the quality of life and pain scores following the Lapiplasty® Procedure.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Each subject will undergo the Lapiplasty® Procedure. The key surgical steps of the Lapiplasty® Procedure are releasing the 1st TMT joint, anatomical correction of the 3-plane deformity, bone preparation using the Lapiplasty® Cut Guide , provisional fixation and multiplanar permanent fixation with the BIPLANAR™ Plate.

It is common for people who undergo a Lapidus Arthrodesis to be non-weight-bearing for 6-8 weeks following the surgical procedure. This time allows the bones to properly fuse together. During this 6-8 week period, people can be limited in the typical day-to-day activities they participate in, such as walking, shopping and working.

The Lapiplasty® System Implants may allow subjects to bear weight earlier than traditional procedures without negatively effecting healing/union of the joint. By allowing people to bear weight earlier than traditional methods, it is possible that people will have the opportunity to resume typical day-to-day activities faster than usual.

This study will investigate the Lapiplasty® Procedure and the Lapiplasty® System Implants with early weight-bearing. The study preference is that subject will be placed in a walking CAM boot and allowed to start protected weight bearing no later than 3 weeks after surgery. Subject can begin protected bearing weight in a CAM boot as early as the day of surgery. Subject will return to weight-bearing in shoe (running or another athletic shoe) and full unrestricted activity as directed by the physician based on the clinical stability and subject ability to safely begin weight-bearing and unrestricted activities.

Recommended Approach for Post-Operative Care and Weight-Bearing Instructions

  • Subject may be either bandaged, put in splint/cast or put in CAM boot at the time of surgery. If subject is fitted with CAM boot at discharge, the patient should be provided instructions on how to begin protected weight-bearing.
  • Subject is instructed to remain off the operative foot as much as possible for the first few days post-op. This is to limit bleeding and swelling and to allow soft tissues to recover.
  • Subject may leave the surgery facility with crutches, walker, rolling knee scooter or wheelchair.
  • At the first post-op visit (0-3 weeks), bandages are removed, and the subject can be allowed to shower. Subject may wear an athletic sock. No bandages or splints are needed. The subject should be reminded of post-op care of the foot/surgical site.
  • At the first post-op visit (0-3 weeks), the subject is fitted with a CAM boot (if the subject was not fitted for a CAM boot at discharge). Subject should be provided with instructions on how to begin protected weight-bearing in the CAM boot and acceptable activities:

    • Patient is instructed to put weight on foot as tolerated in the restrictive boot.
    • Patient is instructed not to roll forward onto the big toe and should remain on flat foot.
    • Patient is instructed to remove the CAM boot multiple times daily and perform range of motion exercises for ankle and foot.
  • At the 6 week post-op visit, if the subject is clinically stable, subject can transition from the boot to a shoe (running or another athletic shoe). The transition from boot to shoe may occur over a period of days/weeks, depending on subject healing and tolerance. Subject is instructed that they can walk normally but are not to stand on toes, run, jump or do any other high impact activity
  • At the 4 month post-op visit, subject is allowed to begin low impact exercise if they are clinically stable.

Study Type

Interventional

Enrollment (Actual)

183

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Greeley, Colorado, United States, 80634
        • Foot & Ankle Center of Northern Colorado
    • Iowa
      • Ankeny, Iowa, United States, 50023
        • Foot & Ankle Center of Iowa
    • Missouri
      • Jefferson City, Missouri, United States, 65109
        • Jefferson City Medical Group, P.C.
    • Nevada
      • Las Vegas, Nevada, United States, 89121
        • Desert Orthopaedic Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19106
        • University of Pennsylvania/Penn Medicine
    • Texas
      • Dallas, Texas, United States, 75390
        • UT Southwestern
      • Frisco, Texas, United States, 75034
        • Stonebriar Foot & Ankle

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 58 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male and females between the ages 14 and 58 years at the time of consent
  • Closed physeal plates at the time of consent
  • Intermetatarsal angle is between 10.0 ̊ - 22.0 ̊
  • Hallux valgus angle is between 16.0 ̊ - 40.0 ̊
  • Willing and able to adhere to early weight-bearing instructions post-operatively
  • Capable of completing self - administered questionnaires
  • Acceptable surgical candidate, including use of general anesthesia
  • Female patients must be of non-child bearing potential or have a negative pregnancy test within 7 days prior to index procedure
  • Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Previous surgery for hallux valgus on operative side
  • Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe or lesser toes/digits)
  • Additional arthrodesis outside the first tarsometatarsal joint (other than: arthrodesis between the medial cuneiform and intermediate cuneiform and/or base of 2nd metatarsal; arthrodesis of hammertoe proximal interphalangeal joint or lesser toes/digits)
  • Moderate or Severe osteoarthritis of the MTP joint based on radiographic imaging (including lack of evident crista) or positive grind test
  • Symptomatic flatfoot or asymptomatic flatfoot (defined as calcaneal inclination <5 ̊and talonavicular subluxation/uncovering >50%)
  • BMI >40 kg/m²
  • Current nicotine user, including current use of nicotine patch
  • Current clinical diagnosis of diabetes with fasting plasma glucose > 126 mg/dL and/or HbA 1c ≥7.0
  • Current clinical diagnosis of peripheral neuropathy or by assessment on 4 - point monofilament test
  • Current clinical diagnosis of fibromyalgia
  • Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD)
  • Current uncontrolled hypothyroidism
  • Previously sensitized to titanium
  • Currently taking oral steroids or rheumatoid biologics
  • Currently taking immunosuppressant drugs
  • Insufficient quantity or quality of bone to permit stabilization, conditions that retard healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease
  • Active, suspected or latent infection in the affected area
  • Use of synthetic or allogenic bone graft substitutes
  • Current diagnosis of metatarsus adductus (defined as MAA ≥ 23 ̊)
  • Scheduled to undergo a same - bilateral procedure. Patient agrees to refrain from the Lapiplasty® Procedure (or other hallux valgus procedures) on contralateral foot for minimum of 6 months post index procedure
  • Patient has previously been enrolled into this study for a contralateral procedure
  • Scheduled for any concomitant procedure that would alter patient's ability to early weight-bear post-procedure
  • Patient is actively involved with a workman's compensation case or is currently involved in litigation
  • Patient is currently or has participated in a clinical study in the last 30 days prior to signing
  • Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Lapiplasty
All study participants receiving Lapiplasty procedure
Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radiographic recurrence of hallux valgus
Time Frame: 24 Months
Defined as IMA ≥ 12, HVA ≥ 20 and TSP as ≥ 4 at 24 Months post Lapiplasty Procedure
24 Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in radiographic angular/positional alignment before and after the Lapiplasty Procedure
Time Frame: Pre-operatively, 6 Weeks, 4 Months, 6 Months, 12 Months, 24 Months, 36 Month, 48 Months, 60 Months
Intermetatarsal Angle (IMA), Hallux Valgus Angle (HVA) and Tibial Sesamoid Position (TSP)
Pre-operatively, 6 Weeks, 4 Months, 6 Months, 12 Months, 24 Months, 36 Month, 48 Months, 60 Months
Clinical/radiographic healing
Time Frame: 12 Months
Evaluate clinical/radiographic healing (union vs non-union). Non-union defined as lucency at TMT joint, hardware failure and/or loss of correction, plus clinical pain at first TMT joint at 12 Months post-Lapiplasty Procedure
12 Months
Clinical complications
Time Frame: 24 Months
Complications due to the Lapiplasty procedure device or post-operative protocol or health conditions that could affect other health outcomes
24 Months
Time to start of weight-bearing in boot
Time Frame: 0-3 Weeks
The time needed for a study subject to begin bearing weight in a boot after the Lapiplasty Procedure
0-3 Weeks
Time to start of weight-bearing in shoes
Time Frame: 0-12 Weeks
The time needed for a study subject to begin bearing weight in a shoe after the Lapiplasty Procedure
0-12 Weeks
Time to return to full unrestricted activity
Time Frame: 6 Weeks to 12 Months
The time needed for a study subject to return to full unrestricted activity after the Lapiplasty Procedure
6 Weeks to 12 Months
Change in Visual Analog Scale (VAS) Pain Score
Time Frame: Pre-operatively, 6 Weeks, 4 Months, 6 Months, 12 Months, 24 Months, 36 Month, 48 Months, 60 Months
Patient reported foot pain intensity/0 (no pain) - 10 (worst possible pain)
Pre-operatively, 6 Weeks, 4 Months, 6 Months, 12 Months, 24 Months, 36 Month, 48 Months, 60 Months
Change in PROMIS-29 score across multiple time-points
Time Frame: Pre-operatively, 6 Months, 12 Months, 24 Months
Patient-Reported Outcomes Measurement Information System (PROMIS-29 Profile v2.1)/lowest possible score 29 - highest possible score 145. High scores mean more of the concept being measured.
Pre-operatively, 6 Months, 12 Months, 24 Months
Change in PROMIS-25 score across multiple time-points
Time Frame: Pre-operatively, 6 Months, 12 Months, 24 Months
Patient-Reported Outcomes Measurement Information System (PROMIS-25 Profile v2.0)/lowest possible score 25 - highest possible score 135. High scores mean more of the concept being measured.
Pre-operatively, 6 Months, 12 Months, 24 Months
Change in MOxFQ Foot Problems score across multiple time-points
Time Frame: Pre-operatively, 6 Months, 12 Months, 24 Months
Manchester-Oxford Foot Questionnaire (MOxFQ)/0 (minimum raw score) - 64 (maximum raw score). Raw score is converted to a metric of 0 - 100 with higher score representing greater severity
Pre-operatively, 6 Months, 12 Months, 24 Months
Change in Range of Motion
Time Frame: 12 Months, 24 Months
1st MTP dorsiflexion and 1st MTP plantarflexion
12 Months, 24 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dane Wukich, MD, UTSW

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 6, 2018

Primary Completion (Actual)

May 1, 2023

Study Completion (Estimated)

May 31, 2026

Study Registration Dates

First Submitted

November 7, 2018

First Submitted That Met QC Criteria

November 9, 2018

First Posted (Actual)

November 14, 2018

Study Record Updates

Last Update Posted (Actual)

September 21, 2023

Last Update Submitted That Met QC Criteria

September 19, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bunion

Clinical Trials on Lapiplasty

3
Subscribe